An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results

Clin Microbiol Infect. 2022 Sep;28(9):1293-1296. doi: 10.1016/j.cmi.2022.04.016. Epub 2022 May 7.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • Drug Combinations
  • Drug Therapy, Combination
  • Humans
  • Hydroxychloroquine* / therapeutic use
  • Interferon beta-1a
  • Lopinavir / therapeutic use
  • Ritonavir / therapeutic use

Substances

  • Antiviral Agents
  • Drug Combinations
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Hydroxychloroquine
  • Ritonavir
  • Interferon beta-1a